Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. (BNXTF) is a bioscience innovator developing advanced drug delivery platforms for autoimmune and neurological conditions. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on BioNxt’s sublingual thin-film technologies, transdermal delivery systems, and regulatory progress across global markets. Key updates include partnership agreements with European CRDMOs, intellectual property filings, and clinical pipeline advancements targeting conditions like multiple sclerosis and lupus nephritis.
All content undergoes strict verification to ensure accuracy and relevance. Regular updates cover:
• Strategic collaborations with pharmaceutical partners
• Regulatory submissions and quality compliance achievements
• Product development milestones in drug delivery innovation
• Intellectual property portfolio expansions
Bookmark this page for direct access to BioNxt’s official communications and analyzed market developments. For comprehensive investment research, combine these updates with SEC filings and financial disclosures.
BioNxt Solutions (BNXTF) has received formal notice from the European Patent Office (EPO) of their intention to grant the company's core patent for sublingual delivery of anticancer drugs treating autoimmune neurodegenerative diseases. The patent is particularly significant for BNT23001, their lead product - a sublingual thin-film formulation of Cladribine designed to treat multiple sclerosis (MS).
The company is advancing patent protection through the EPO, Eurasian Patent Organization, and independent nations including Australia, Canada, New Zealand, USA, and Japan. This intellectual property will support BioNxt's pipeline of sublingual products targeting various autoimmune diseases including MS, myasthenia gravis, lupus nephritis, and rheumatoid arthritis.
BioNxt Solutions (BNXTF) has announced the consolidation of its research, development, and commercialization activities at the Gen-Plus CRDO facility in Munich, Germany. The integration provides access to a 1,000-square-meter state-of-the-art laboratory space equipped for high-potency pharmaceutical development and GMP-compliant processes.
The company will leverage Gen-Plus's advanced infrastructure to enhance its drug delivery systems, focusing on their lead product BNT23001, a sublingual thin-film formulation of Cladribine for multiple sclerosis treatment. Immediate plans include preparation for human bioequivalence studies, including placebo trials, product transfer, manufacturing upscaling, and analytical validation.
BioNxt Solutions (BNXTF) has received acceptance of its first national level patent filing from the Eurasian Patent Organization (EAPO). The patent, which previously received a positive international examination report from the European Patent Office in September 2024, covers sublingual delivery of anticancer drugs for treating autoimmune neurodegenerative diseases.
The patent notably includes BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for multiple sclerosis treatment. The EAPO protection extends across eight member states: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan. The company is also pursuing patent protection in Australia, Canada, New Zealand, USA, and Japan to support commercialization opportunities for its pipeline of sublingual products targeting various autoimmune diseases.
BioNxt Solutions (CSE:BNXT, OTC:BNXTF) is advancing preparations for a human bioequivalence study of its lead Multiple Sclerosis treatment, BNT23001. The product is a proprietary sublingual thin-film formulation of Cladribine designed to treat MS.
The company has acquired the necessary Cladribine active pharmaceutical ingredient to complete technology transfer with Gen-Plus, its European Contract Research and Development Organization in Munich, Germany. The upcoming bioequivalence study is expected to be completed in under 30 days once initiated.
Preclinical studies have shown high absorption rates and bioequivalence compared to existing oral tablet therapies. BNT23001's sublingual thin-film format offers key advantages including convenient administration, rapid absorption through sublingual mucosa, and improved patient compliance.
BioNxt Solutions has successfully closed the final tranche of its fully subscribed convertible debenture unit private placement, raising total gross proceeds of $2.5 million. The offering consisted of two tranches: first tranche of 3.2 million units for $1.6 million and second tranche of 1.8 million units for $900,000.
Each debenture unit includes a $0.50 principal amount of 8.0% unsecured convertible debentures and one common share purchase warrant. The warrants are exercisable at $0.60 per share until February/March 2027. The debentures are convertible into common shares at $0.50 per share before maturity.
The company paid $200,000 in fees and issued 400,000 finder's warrants to Canaccord Genuity Corp. Net proceeds will fund product development, commercialization, IP filings, debt repayment, and working capital.
BioNxt Solutions has successfully closed the first tranche of its non-brokered private placement, raising $1.6 million through convertible debenture units. Each unit comprises a $0.50 principal amount of 8.0% unsecured convertible debentures and one common share purchase warrant.
The debentures feature an 8.0% annual interest rate, payable at maturity in two years, and are convertible to common shares at $0.50 per share. Warrants are exercisable at $0.60 per share until February 28, 2027.
As part of the offering, the company paid $128,000 in cash fees and issued 256,000 finder warrants to Canaccord Genuity Corp. The proceeds will fund product development, commercialization, intellectual property filings, debt repayment, and working capital.
BioNxt Solutions has announced a non-brokered private placement of debenture units to raise up to $2.5 million. Each debenture unit consists of $0.50 in principal amount, bearing an 8% annual interest rate for two years, and is convertible into common shares. The units also include one Common Share purchase warrant exercisable at $0.60 for two years.
The company may pay interest through common shares at $0.50 per share. Additionally, BioNxt plans to issue up to 400,000 compensation warrants at $0.50 per warrant to eligible finders, along with up to 8% finder's fee in cash. All securities will have a four-month and one-day hold period from issuance. The offering's completion is subject to regulatory approvals.
BioNxt Solutions (CSE:BNXT)(OTC:BNXTF) has clarified its January 31, 2025 news release regarding promotional activities. The company has engaged two firms for investor relations services:
1. Apaton Finance GmbH will provide services from February-June 2025 for two payments of €10,000 each, plus 50,000 stock options at $0.50 per share. Services include brand visibility enhancement and German market investor engagement.
2. Cayo Ventures GmbH will provide German language engagement and digital marketing services from February-March 2025 for €20,000 per week (subject to company discretion), plus 150,000 stock options at $0.50 per share.
Both option grants vest 25% quarterly over 12 months with a two-year exercise period and are subject to a four-month hold period.
FAQ
What is the current stock price of BioNxt Solutions (BNXTF)?
What is the market cap of BioNxt Solutions (BNXTF)?
